Aggregatibacter is inversely associated with inflammatory mediators in sputa of patients with chronic airway diseases and reduces inflammation in vitro.
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
24
01
2024
accepted:
18
09
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
12
10
2024
Statut:
epublish
Résumé
Chronic airway disease (CAD) is characterized by chronic airway inflammation and colonization of the lungs by pro-inflammatory pathogens. However, while various other bacterial species are present in the lower airways, it is not fully understood how they influence inflammation. We aimed to identify novel anti-inflammatory species present in lower airway samples of patients with CAD. Paired sputum microbiome and inflammatory marker data of adults with CAD across three separate cohorts (Australian asthma and bronchiectasis, Scottish bronchiectasis) was analyzed using Linear discriminant analysis Effect Size (LEfSE) and Spearman correlation analysis to identify species associated with a low inflammatory profile in patients. We identified the genus Aggregatibacter as more abundant in patients with lower levels of airway inflammatory markers in two CAD cohorts (Australian asthma and bronchiectasis). In addition, the relative abundance of Aggregatibacter was inversely correlated with sputum IL-8 (Australian bronchiectasis) and IL-1β levels (Australian asthma and bronchiectasis). Subsequent in vitro testing, using a physiologically relevant three-dimensional lung epithelial cell model, revealed that Aggregatibacter spp. (i.e. A. actinomycetemcomitans, A. aphrophilus) and their cell-free supernatant exerted anti-inflammatory activity without influencing host cell viability. These findings suggest that Aggregatibacter spp. might act to reduce airway inflammation in CAD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic airway disease (CAD) is characterized by chronic airway inflammation and colonization of the lungs by pro-inflammatory pathogens. However, while various other bacterial species are present in the lower airways, it is not fully understood how they influence inflammation. We aimed to identify novel anti-inflammatory species present in lower airway samples of patients with CAD.
METHODS
METHODS
Paired sputum microbiome and inflammatory marker data of adults with CAD across three separate cohorts (Australian asthma and bronchiectasis, Scottish bronchiectasis) was analyzed using Linear discriminant analysis Effect Size (LEfSE) and Spearman correlation analysis to identify species associated with a low inflammatory profile in patients.
RESULTS
RESULTS
We identified the genus Aggregatibacter as more abundant in patients with lower levels of airway inflammatory markers in two CAD cohorts (Australian asthma and bronchiectasis). In addition, the relative abundance of Aggregatibacter was inversely correlated with sputum IL-8 (Australian bronchiectasis) and IL-1β levels (Australian asthma and bronchiectasis). Subsequent in vitro testing, using a physiologically relevant three-dimensional lung epithelial cell model, revealed that Aggregatibacter spp. (i.e. A. actinomycetemcomitans, A. aphrophilus) and their cell-free supernatant exerted anti-inflammatory activity without influencing host cell viability.
CONCLUSIONS
CONCLUSIONS
These findings suggest that Aggregatibacter spp. might act to reduce airway inflammation in CAD patients.
Identifiants
pubmed: 39395980
doi: 10.1186/s12931-024-02983-z
pii: 10.1186/s12931-024-02983-z
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
368Subventions
Organisme : Research Foundation Flanders
ID : 1S34622N
Organisme : National Health and Medical Research Council
ID : APP2008625
Organisme : Fonds Wetenschappelijk Onderzoek
ID : G024423N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1SC3722N
Organisme : Ghent University Industrial Research Fund
ID : F2020/IOF-StarTT/103
Informations de copyright
© 2024. The Author(s).
Références
Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015;14:419–30.
pubmed: 25814049
doi: 10.1016/j.jcf.2015.03.003
Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54.
Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Semin Respir Crit Care Med. 2021;42:499–512.
pubmed: 34261175
doi: 10.1055/s-0041-1730891
Côté A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol. 2020;179:114112.
pubmed: 32598948
doi: 10.1016/j.bcp.2020.114112
Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017;10:299–306.
pubmed: 27966551
doi: 10.1038/mi.2016.108
Huffnagle GB, Dickson RP. The bacterial microbiota in inflammatory lung diseases. Clin Immunol. 2015;159:177–82.
pubmed: 26122174
pmcid: 5081074
doi: 10.1016/j.clim.2015.05.022
Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;20:1279–90.
pubmed: 31501577
doi: 10.1038/s41590-019-0451-9
N’Guessan PD, Haarmann H, Steiner T, Heyl K, Schreiber F, Heinrich A, et al. The Moraxella catarrhalis-induced pro-inflammatory immune response is enhanced by the activation of the epidermal growth factor receptor in human pulmonary epithelial cells. Biochem Biophys Res Commun. 2014;450:1038–44.
Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010;9:51–8.
Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol. 2012;107(10):459–71. (2012).
doi: 10.1038/nrmicro2801
Dickson RP, Huffnagle GB. The Lung Microbiome: New principles for respiratory bacteriology in Health and Disease. PLoS Pathog. 2015;11:e1004923.
pubmed: 26158874
pmcid: 4497592
doi: 10.1371/journal.ppat.1004923
Man WH, De Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15.
Madapoosi SS, et al. Lung microbiota and metabolites collectively associate with clinical outcomes in milder Stage Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2022;206:427–39.
pubmed: 35536732
pmcid: 11418810
doi: 10.1164/rccm.202110-2241OC
Vissers M, De Groot R, Ferwerda G. Severe viral respiratory infections: are bugs bugging? Mucosal Immunol. 2014;7:227–38.
pubmed: 24220300
doi: 10.1038/mi.2013.93
Dickson RP, Martinez FJ, Huffnagle GB. The role of the Microbiome in exacerbations of Chronic Lung diseases. Lancet. 2014;384:691.
pubmed: 25152271
pmcid: 4166502
doi: 10.1016/S0140-6736(14)61136-3
Dicker AJ, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2021;147:158–67.
pubmed: 32353489
doi: 10.1016/j.jaci.2020.02.040
Goeteyn E, et al. Commensal bacteria of the lung microbiota synergistically inhibit inflammation in a three-dimensional epithelial cell model. Front Immunol. 2023;14:1176044.
pubmed: 37168857
pmcid: 10164748
doi: 10.3389/fimmu.2023.1176044
Rigauts C, Aizawa J, Taylor SL, Rogers GB, Govaerts M, Cos P, , et al. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur Respir J. 2021;59.
Tony-Odigie A, Wilke L, Boutin S, Dalpke AH, Yi B. Commensal Bacteria in the cystic fibrosis airway microbiome reduce P. aeruginosa induced inflammation. Front Cell Infect Microbiol. 2022;12:824101.
Bertelsen A, Elborn SJ, Schock BC. Toll like receptor signalling by Prevotella histicola activates alternative NF-κB signalling in cystic fibrosis bronchial epithelial cells compared to P. aeruginosa. PLoS ONE. 2020;15:e0235803.
pubmed: 33031374
pmcid: 7544055
doi: 10.1371/journal.pone.0235803
Gupta S et al. Amplicon sequencing provides more accurate microbiome information in healthy children compared to culturing. Commun. Biol. 2019 21 2, 1–7 (2019).
Toma I, et al. Single-molecule long-read 16S sequencing to characterize the lung microbiome from mechanically ventilated patients with suspected pneumonia. J Clin Microbiol. 2014;52:3913–21.
pubmed: 25143582
pmcid: 4313225
doi: 10.1128/JCM.01678-14
Gibson PG, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet (London England). 2017;390:659–68.
pubmed: 28687413
doi: 10.1016/S0140-6736(17)31281-3
Serisier DJ, et al. Effect of Long-term, low-dose erythromycin on Pulmonary exacerbations among patients with non–cystic fibrosis bronchiectasis: the BLESS Randomized Controlled Trial. JAMA. 2013;309:1260–7.
pubmed: 23532242
doi: 10.1001/jama.2013.2290
Dicker AJ, et al. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respir Med. 2021;9:885–96.
pubmed: 33961805
doi: 10.1016/S2213-2600(20)30557-9
Taylor SL, Leong LE, Mobegi FM, Choo JM, Wesselingh S, Yang IA, et al. Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med. 2019;200:309–17.
Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2:988–96.
pubmed: 25458200
doi: 10.1016/S2213-2600(14)70213-9
Barrila J, et al. Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol. 2010;8:791–801.
pubmed: 20948552
doi: 10.1038/nrmicro2423
Carterson AJ, Honer zu Bentrup K, Ott CM, Clarke MS, Pierson DL, et al. A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for Pseudomonas aeruginosa pathogenesis. Infect Immun. 2005;73:1129–40.
Crabbé A, Liu Y, Matthijs N, Rigole P, De La Fuente-Nùñez C, Davis R, et al. Antimicrobial efficacy against Pseudomonas aeruginosa biofilm formation in a three-dimensional lung epithelial model and the influence of fetal bovine serum. Sci Rep. 2017;7:1–13.
Van den Bossche S, Vandeplassche E, Ostyn L, Coenye T, Crabbé A. Bacterial interference with Lactate Dehydrogenase Assay leads to an underestimation of Cytotoxicity. Front Cell Infect Microbiol. 2020;10:1–11.
Maes M, et al. Measurement of apoptotic and necrotic cell death in primary hepatocyte cultures. Methods Mol Biol. 2015;1250:349–61.
pubmed: 26272157
pmcid: 4579552
doi: 10.1007/978-1-4939-2074-7_27
Vinken M, Blaauboer BJ. In vitro testing of basal cytotoxicity: establishment of an adverse outcome pathway from chemical insult to cell death. Toxicol in Vitro. 2017;39:104–10.
pubmed: 27939612
doi: 10.1016/j.tiv.2016.12.004
Segata N, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.
pubmed: 21702898
pmcid: 3218848
doi: 10.1186/gb-2011-12-6-r60
Jafari M, Ansari-Pour N. Why, when and how to adjust your P values? Cell J. 2019;20:604–7.
pubmed: 30124010
Bertelsen A, Elborn JS, Schock BC. Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells. J Cyst Fibros. 2021;20:682–91.
pubmed: 34112603
doi: 10.1016/j.jcf.2021.04.012
Li L, Mac Aogain M, Xu T, Jaggi TK, Chan LL, Qu J, et al. Neisseria species as pathobionts in bronchiectasis. Cell Host Microbe. 2022;30:1311–27.
Nordenhäll C, et al. Airway inflammation following exposure to diesel exhaust: a study of time kinetics using induced sputum. Eur Respir J. 2000;15:1046.
pubmed: 10885423
doi: 10.1034/j.1399-3003.2000.01512.x
Pedersen F, et al. Influence of cell quality on inflammatory biomarkers in COPD Sputum Supernatant. Int J Chron Obstruct Pulmon Dis. 2021;16:487–93.
pubmed: 33688174
pmcid: 7935341
doi: 10.2147/COPD.S284938
Nørskov-Lauritsen N. Classification, identification, and clinical significance of Haemophilus and Aggregatibacter species with host specificity for humans. Clin Microbiol Rev. 2014;27:214–40.
Murra M, et al. Whole-genome sequencing of Aggregatibacter species isolated from human clinical specimens and description of Aggregatibacter Kilianii sp. nov. J Clin Microbiol. 2018;56–1128.
Durack J, et al. Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. J Allergy Clin Immunol. 2020;146:1016–26.
pubmed: 32298699
pmcid: 7554083
doi: 10.1016/j.jaci.2020.03.028
Wang Z, et al. Inflammatory endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and exacerbations a Multicohort Longitudinal Analysis. Am J Respir Crit Care Med. 2021;203:1488–502.
pubmed: 33332995
pmcid: 8483235
doi: 10.1164/rccm.202009-3448OC
Liu H, et al. Association of sputum microbiome with clinical outcome of initial antibiotic treatment in hospitalized patients with acute exacerbations of COPD. Pharmacol Res. 2020;160:105095.
pubmed: 32730904
doi: 10.1016/j.phrs.2020.105095
Xue Q, et al. Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study. Sci Rep. 2023;13:5715.
pubmed: 37029178
pmcid: 10080507
doi: 10.1038/s41598-023-32901-0
Huang D, et al. The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am J Cancer Res. 2019;9:2047.
pubmed: 31598405
pmcid: 6780665
Wang K, et al. A preliminary study of Microbiota Diversity in Saliva and Bronchoalveolar Lavage Fluid from patients with primary bronchogenic carcinoma. Med Sci Monit. 2019;25:2819–34.
pubmed: 30994108
pmcid: 6482867
doi: 10.12659/MSM.915332
Liu Y, et al. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res. 2018;8:1775.
pubmed: 30323970
pmcid: 6176189
Xiao Q, et al. Characterization of the microbiome and host’s metabolites of the Lower Respiratory Tract during Acute Community-Acquired Pneumonia identifies potential novel markers. Infect Drug Resist. 2023;16:581–94.
pubmed: 36726385
pmcid: 9885967
doi: 10.2147/IDR.S394779
Cheung MK, et al. Sputum Microbiota in Tuberculosis as revealed by 16S rRNA pyrosequencing. PLoS ONE. 2013;8:e54574.
pubmed: 23365674
pmcid: 3554703
doi: 10.1371/journal.pone.0054574
Ramsey MM, Whiteley M. Polymicrobial interactions stimulate resistance to host innate immunity through metabolite perception. Proc. Natl. Acad. Sci. U. S. A. 106, 1578–1583 (2009).
Maraki S, Papadakis IS, Chronakis E, Panagopoulos D, Vakis A. Aggregatibacter aphrophilus brain abscess secondary to primary tooth extraction: case report and literature review. J Microbiol Immunol Infect. 2016;49:119–22.
pubmed: 24529567
doi: 10.1016/j.jmii.2013.12.007
Shilo S, Kassis I, Hakim F, Shachor-Meyouhas Y. Aggregatibacter actinomycemcomitans pneumonia in children: two case reports and a review of the literature. Pediatr Infect Dis J. 2015;34:100–2.
pubmed: 25068288
doi: 10.1097/INF.0000000000000493
Hagiwara SI, Fujimaru T, Ogino A, Takano T, Sekijima T, Kagimoto S, et al. Lung abscess caused by infection of Actinobacillus actinomycetemcomitans. Pediatr Int. 2009;51:748–51.
Chen AC, Liu CC, Yao WJ, Chen CT, Wang JY. Actinobacillus actinomycetemcomitans pneumonia with chest wall and subphrenic abscess. Scand J Infect Dis. 1995;27:289–90.
pubmed: 8539555
doi: 10.3109/00365549509019023
Kaplan AH, Weber DJ, Oddone EZ, Perfect JR. Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis. 1989;11:46–63.
pubmed: 2644690
doi: 10.1093/clinids/11.1.46
Abusleme L, Hong B-Y, Dupuy AK, Strausbaugh LD, Diaz PI. Influence of DNA extraction on oral microbial profiles obtained via 16S rRNA gene sequencing. J Oral Microbiol. 2014;6:23990.
doi: 10.3402/jom.v6.23990
Bukin YS, et al. The effect of 16S rRNA region choice on bacterial community metabarcoding results. Sci Data 2019. 2019;61(6):1–14.
Zheng W, et al. An accurate and efficient experimental approach for characterization of the complex oral microbiota. Microbiome. 2015;3:48.
pubmed: 26437933
pmcid: 4593206
doi: 10.1186/s40168-015-0110-9
Ceccarani C, Severgnini MA, comparison between Greengenes. SILVA, RDP, and NCBI reference databases in four published microbiota datasets. bioRxiv 2023.04.12.535864 (2023) https://doi.org/10.1101/2023.04.12.535864
Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res. 2012;160:258–66.
pubmed: 22683412
pmcid: 3440512
doi: 10.1016/j.trsl.2012.02.005
Stressmann FA, et al. Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. J Clin Microbiol. 2011;49:281–91.
pubmed: 21068277
doi: 10.1128/JCM.01650-10
Patas K, Douros K, Priftis KN, Ioannidis A, Nikolaou C, Chatzipanagiotou S. Isolation of Aggregatibacter aphrophilus from bronchoalveolar lavage in a paediatric patient presenting with haemoptysis. New Microbes New Infect. 2019;29:100509.
Ramsheh MY, et al. Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe. 2021;2:e300–10.
pubmed: 35544166
doi: 10.1016/S2666-5247(21)00035-5
Myers S, et al. Immunomodulatory streptococci that inhibit CXCL8 secretion and NFκB activation are common members of the oral microbiota. J Med Microbiol. 2021;70:001329.
pubmed: 33734952
pmcid: 8346732
doi: 10.1099/jmm.0.001329
Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K.. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:1–22.
Cowley ES, Kopf SH, Lariviere A, Ziebis W, Newman DK. Pediatric cystic fibrosis sputum can be chemically dynamic, anoxic, and extremely reduced due to hydrogen sulfide formation. MBio 6, (2015).
Ahlstrand T, Kovesjoki L, Maula T, Oscarsson J, Ihalin R. Aggregatibacter actinomycetemcomitans LPS binds human interleukin-8. J Oral Microbiol. 2019;11:1549931.
pubmed: 34917288
doi: 10.1080/20002297.2018.1549931
Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Research. 2019;8:557.
doi: 10.12688/f1000research.18411.1
Moriel DG, Heras B, Paxman JJ, Lo AW, Tan L, Sullivan MJ, et al. Molecular and structural characterization of a novel Escherichia coli interleukin receptor mimic protein. mBio. 2016;7:e02046.
Grassi L, et al. Recreating chronic respiratory infections in vitro using physiologically relevant models. Eur Respir Rev. 2024;33.